ClinicalTrials.gg
CompletedNCT04732221Updated May 25, 2025Results posted

A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

A Phase 2/3 interventional study of Frespaciguat and Placebo to Frespaciguat in Pulmonary Arterial Hypertension and Hypertension, Pulmonary, sponsored by Merck Sharp & Dohme LLC. Completed at 91 sites in 18 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc — 3 open to participants now, 5 under way, 1 of them phase 3. Pulmonary Arterial Hypertension · Merck & Co., Inc.

Enrollment
5th of 17
168 · median 46
Started
2021
with 3 others
Phase 2/3
Only one
of the 17
Registered
8th of 17
by date

Among the 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc, this one is the 5th largest by enrollment, is one of 4 that started in 2021, is the only one in phase 2/3, and was the 8th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc, or all of them as a file.
02

Study summary

This is a two-part (Phase 2/Phase 3) study of frespaciguat, an inhaled soluble guanylate cyclase stimulator, in participants with pulmonary arterial hypertension (PAH).

The first part (Phase 2) will assess three different doses of frespaciguat compared to placebo in a base period of 12 weeks, followed by comparison of three different doses of frespaciguat during an optional 40 month extension period. The treatment dose with the best efficacy and safety profile in the phase 2 cohort base period will be selected for use in the second part (Phase 3) of the study. The primary hypothesis of Phase 2 is that at least one frespaciguat dose is superior to placebo in reducing pulmonary vascular resistance (PVR) from baseline at week 12.

The purpose of the second part (Phase 3) of the study is to confirm the efficacy, safety, and tolerability of frespaciguat at the selected dose compared to placebo during a 12 week base period followed by an extension period of up to 5 years. The primary hypothesis of Phase 3 is that frespaciguat is superior to placebo in increasing 6-minute walk distance (6MWD) from baseline at week 12. Due to sponsor's decision this phase/part was not conducted.

03

Conditions studied

  • Pulmonary Arterial Hypertension
  • Hypertension, Pulmonary
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pulmonary arterial hypertension (PAH) in one of the following groups:

    • Idiopathic PAH
    • Heritable PAH
    • Drug and toxin-induced PAH
    • PAH associated with connective tissue disease, infection, or congenital heart disease.
  • Diagnosis of PAH documented by right heart catheterization (RHC).
  • Eligibility RHC meeting all of the following criteria:

    • Mean pulmonary artery pressure (mPAP) ≥25 mmHg
    • Pulmonary vascular resistance (PVR) of ≥3 Wood units
    • Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) ≤15 mmHg.
  • World Health Organization functional class (WHO-FC) symptoms between Class II and IV.
  • Two 6-Minute walk distance (6MWD) measurements between 150 and 500 meters, one at screening and one at randomization.
  • Stable concomitant background PAH-specific therapy.
  • (BMI) between 18.5 kg/m² and 40 kg/m² .
  • Agree to be abstinent from heterosexual intercourse or use during the intervention period and for at least 14 days after the last dose of study intervention.
  • Female participants may not be pregnant or breastfeeding.

Exclusion criteria

Exclusion Criteria:

  • Group 2 to 5 pulmonary hypertension.
  • PAH in one of the following groups:

    • Long term responders to calcium channel blockers
    • Overt features of venous/capillary involvement
  • Evidence of more-than-mild obstructive lung disease.
  • Evidence of more-than-mild parenchymal lung disease.
  • Evidence of more-than-mild obstructive sleep apnea (OSA) that is untreated.
  • Evidence or history of left heart disease, including any of the following:

    • (LVEF) ≤45%
    • Moderate or severe left-sided valvular disease (aortic or mitral valve stenosis or regurgitation)
    • Significant left ventricular diastolic dysfunction on echocardiographic evaluation
  • Presence of 3 or more of the following risk factors for heart failure with preserved ejection fraction: >30 kg/m², essential systemic hypertension, diabetes mellitus of any type, or coronary artery disease.
  • Oxygen saturation measured by pulse oximetry (SpO₂) \<90%, despite supplemental oxygen therapy.
  • Chronic renal insufficiency ( \<30 mL/min)
  • Chronic liver disease (i.e., B or C), portal hypertension, cirrhosis, or significant hepatic laboratory abnormalities.
  • Current smoker or currently uses electronic cigarettes (vapes).
  • History of cancer, except: nonmelanomatous skin carcinoma or carcinoma in situ of the cervix or other which have been successfully treated, with appropriate follow up, and unlikely to recur for the duration of the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    Phase 2 Cohort Frespaciguat 380 µg

    Participants receive frespaciguat 380 µg via oral inhalation once daily for 12 week base period and for optional 40 month extension period.

    Drug: Frespaciguat

  • Experimental
    Phase 2 Cohort Frespaciguat 100 µg

    Participants receive frespaciguat 100 µg via oral inhalation once daily for 12 week base period and for optional 40 month extension period.

    Drug: Frespaciguat

  • Experimental
    Phase 2 Cohort Frespaciguat 32 µg

    Participants receive frespaciguat 32 µg via oral inhalation once daily for 12 week base period and for optional 40 month extension period.

    Drug: Frespaciguat

  • Placebo comparator
    Phase 2 Cohort Placebo

    Participants receive placebo via oral inhalation once daily for 12 week base period, and one of the MK-5475 doses (380, 100, or 32 µg) for the optional 40 month extension period.

    Drug: Placebo to Frespaciguat

  • Experimental
    Phase 3 Cohort Frespaciguat

    Participants receive one of 3 frespaciguat doses (380, 100 or 32 µg) to be selected at end of the Phase 2 Cohort, administered via oral inhalation once daily for 12-week base period and up to 40 months in the extension period

    Drug: Frespaciguat

  • Placebo comparator
    Phase 3 Cohort Placebo

    Participants receive placebo via oral inhalation once daily for 12 week base period and up to 40 months in the extension period.

    Drug: Placebo to Frespaciguat

Interventions

  • Frespaciguat (soluble guanylate cyclase stimulator) 380 µg, 100 µg or 32 µg administered as dry powder inhalation

  • DrugPlacebo to Frespaciguat

    Placebo administered as dry powder inhalation

06

What researchers measure

Primary outcomes

  1. Phase 2 Cohort: Mean Percent Change From Baseline in Pulmonary Vascular Resistance (PVR) at 12 Weeks

    PVR was calculated in participants after MK-5475 dosing at baseline and Week 12. PVR is assessed by right heart catheterization (RHC). Based on the variables obtained by right heart catheterization (RHC), the percentage change from baseline PVR was calculated. Per protocol, this outcome measure was assessed only for base period and was not assessed during extension period.

    Time frame: At baseline and 12 weeks

  2. Phase 3 Cohort: Mean Change From Baseline in 6-Minute Walk Distance (6MWD) at 12 Weeks

    6MWD is measured by an exercise test known as 6-Minute Walk Test (6MWT) that assesses functional capacity. It measures the distance covered over a time of 6 minutes and is intended to be used as an outcome measure by which to compare changes in excercise capacity. Each participant's 6MWD is to be measured at baseline and at 12 weeks. An increase in the distance walked during the 6MWT indicates improvement in functional exercise capacity.

    Time frame: At baseline and 12 weeks

Secondary outcomes

  1. Phase 2 Cohort: Mean Change From Baseline in 6-Minute Walk Distance (6MWD) at 12 Weeks

    6MWD is measured by an exercise test known as 6-Minute Walk Test (6MWT) that assesses functional capacity. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in exercise capacity. Each participant's 6MWD was measured at baseline and at 12 weeks. An increase in the distance walked during the 6MWT indicates improvement in functional exercise capacity.

    Time frame: At baseline and 12 weeks

  2. Phase 2 Cohort: Mean Change From Baseline in Mean Right Atrial Pressure (mRAP) at 12 Weeks

    mRAP is the blood pressure in the right atrium of the heart. mRAP was assessed by right heart catheterization (RHC).A decrease in mRAP indicates improvement in right ventricular function, reduction of PAH related morbidity.

    Time frame: At baseline and 12 weeks

  3. Phase 2 Cohort: Mean Change From Baseline in Cardiac Index (CI) at 12 Weeks

    The cardiac index (CI) is a hemodynamic measure that represents the cardiac output (CO) of an individual divided by their body surface area (BSA). Cardiac index is assessed by right heart catheterization (RHC). An increase in CI is indicates better right ventricular function and is associated with a reduction of PAH related morbidity and mortality.

    Time frame: At baseline and 12 weeks

  4. Phase 2 Cohort: Mean Change From Baseline in Stroke Volume Index (SVI) at 12 Weeks

    The stroke volume index represents the amount of blood in mL, per square meter of body surface area, that is mobilized with each heart beat. SVI is assessed by RHC. An increase in SVI indicates better right ventricular function and is associated with a reduction of PAH related morbidity and mortality.

    Time frame: At baseline and 12 weeks

  5. Phase 3 Cohort: Mean Change From Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks

    6MWD is measured by an exercise test known as 6-Minute Walk Test (6MWT) that assesses functional capacity. It measures the distance covered over a time of 6 minutes and is intended to be used as an outcome measure by which to compare changes in exercise capacity. Each participant's 6MWD is to be measured at baseline and at 24 weeks. An increase in the distance walked during the 6MWT indicates improvement in functional exercise capacity.

    Time frame: At baseline and 24 weeks

  6. Phase 3 Cohort: Proportion of Participants Whose World Health Organization Functional Class (WHO-FC) is Not Worse at 12 Week Relative to Baseline

    The World Health Organization (WHO) classification of functional status is a measure of disease severity, based on a patient's description of their level of functioning and symptoms of disease in relation to their everyday activity. Patients were to be assigned 1 of 4 WHO-FC, dependent on limits of physical activity. As WHO-FC increases from I to IV, limits of physical activity were to increase.

    Time frame: At baseline and 12 weeks

  7. Phase 2 Cohort: Number of Participants Who Experienced an Adverse Event

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 2.25 years

  8. Phase 2 Cohort: Number of Participants Who Discontinued Study Drug Due to an Adverse Event

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed.

    Time frame: Up to approximately 2.25 years

  9. Phase 3 Cohort: Number of Participants Who Experienced an Adverse Event

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 2.25 years

  10. Phase 3 Cohort: Number of Participants Who Discontinued Study Drug Due to an AE

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed.

    Time frame: Up to approximately 2.25 years

07

Results

Posted Feb 21, 2025

Participant flow

Base Period
Participant flow — Base Period
MilestoneBase Period: PlaceboBase Period: MK-5475 32 µgBase Period: MK-5475 100 µgBase Period: MK-5475 380 µgExtension Period: MK-5475 32 µgExtension Period: MK-5475 100 µgExtension Period: MK-5475 380 μg
Started41424441000
Completed39414341000
Not completed2110000
Withdrew: Death2000000
Withdrew: Withdrawal by subject0110000
Extension Period
Participant flow — Extension Period
MilestoneBase Period: PlaceboBase Period: MK-5475 32 µgBase Period: MK-5475 100 µgBase Period: MK-5475 380 µgExtension Period: MK-5475 32 µgExtension Period: MK-5475 100 µgExtension Period: MK-5475 380 μg
Started0000454644
Completed0000100
Not completed0000444644
Withdrew: Adverse event0000010
Withdrew: Death0000102
Withdrew: Pregnancy0000100
Withdrew: Sponsors decision0000414040
Withdrew: Withdrawal by subject0000152

Outcome measures

PrimaryPhase 2 Cohort: Mean Percent Change From Baseline in Pulmonary Vascular Resistance (PVR) at 12 Weeks

PVR was calculated in participants after MK-5475 dosing at baseline and Week 12. PVR is assessed by right heart catheterization (RHC). Based on the variables obtained by right heart catheterization (RHC), the percentage change from baseline PVR was calculated. Per protocol, this outcome measure was assessed only for base period and was not assessed during extension period.

Time frame:
At baseline and 12 weeks
Reported as:
Least squares mean · Percentage Change
Phase 2 Cohort: Mean Percent Change From Baseline in Pulmonary Vascular Resistance (PVR) at 12 Weeks
Percentage ChangeBase Period: PlaceboBase Period: MK-5475 32 µgBase Period: MK-5475 100 µgBase Period: MK-5475 380 µg
Phase 2 Cohort: Mean Percent Change From Baseline in Pulmonary Vascular Resistance (PVR) at 12 Weeks4.3 ± 4.45-4.9 ± 4.07-17.6 ± 4.07-15.6 ± 5.39
Statistical analysis
  • Base Period: Placebo vs Base Period: MK-5475 32 µg · Robust Regression · p = 0.068 (A 1-sided p-value was obtained from fitting a Robust regression estimate based on a Huber-type M estimator including terms for treatment and WHO-FC (Class II and Class III/IV) at baseline) · Treatment difference: -9.2 · 95% CI -21.3 to 2.9Least Square Mean of the overall treatment difference with 95% confidence interval (CI) was reported
  • Base Period: Placebo vs Base Period: MK-5475 100 µg · Robust Regression · p = <0.001 (based on a Huber-type M estimator including terms for treatment and WHO-FC (Class II and Class III/IV) at baseline) · Treatment difference: -22.0 · 95% CI -33.7 to -10.3Least Square Mean of the overall treatment difference with 95% confidence interval (CI) was reported
  • Base Period: Placebo vs Base Period: MK-5475 380 µg · Robust Regression · p = 0.002 (A 1-sided p-value was obtained from fitting a Robust regression estimate based on a Huber-type M estimator including terms for treatment and WHO-FC (Class II and Class III/IV) at baseline) · Treatment difference: -19.9 · 95% CI -33.4 to -6.4Least Square Mean of the overall treatment difference with 95% confidence interval (CI) was reported
PrimaryPhase 3 Cohort: Mean Change From Baseline in 6-Minute Walk Distance (6MWD) at 12 Weeks

6MWD is measured by an exercise test known as 6-Minute Walk Test (6MWT) that assesses functional capacity. It measures the distance covered over a time of 6 minutes and is intended to be used as an outcome measure by which to compare changes in excercise capacity. Each participant's 6MWD is to be measured at baseline and at 12 weeks. An increase in the distance walked during the 6MWT indicates improvement in functional exercise capacity.

Time frame:
At baseline and 12 weeks

No measurements were reported for this outcome.

SecondaryPhase 2 Cohort: Mean Change From Baseline in 6-Minute Walk Distance (6MWD) at 12 Weeks

6MWD is measured by an exercise test known as 6-Minute Walk Test (6MWT) that assesses functional capacity. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in exercise capacity. Each participant's 6MWD was measured at baseline and at 12 weeks. An increase in the distance walked during the 6MWT indicates improvement in functional exercise capacity.

Time frame:
At baseline and 12 weeks
Reported as:
Mean · Meters
Phase 2 Cohort: Mean Change From Baseline in 6-Minute Walk Distance (6MWD) at 12 Weeks
MetersBase Period: PlaceboBase Period: MK-5475 32 µgBase Period: MK-5475 100 µgBase Period: MK-5475 380 µg
Phase 2 Cohort: Mean Change From Baseline in 6-Minute Walk Distance (6MWD) at 12 Weeks24.6 ± 66.327.4 ± 53.110.8 ± 45.611.3 ± 38.9
SecondaryPhase 2 Cohort: Mean Change From Baseline in Mean Right Atrial Pressure (mRAP) at 12 Weeks

mRAP is the blood pressure in the right atrium of the heart. mRAP was assessed by right heart catheterization (RHC).A decrease in mRAP indicates improvement in right ventricular function, reduction of PAH related morbidity.

Time frame:
At baseline and 12 weeks
Reported as:
Mean · Millimeters of Mercury (mmHg)
Phase 2 Cohort: Mean Change From Baseline in Mean Right Atrial Pressure (mRAP) at 12 Weeks
Millimeters of Mercury (mmHg)Base Period: PlaceboBase Period: MK-5475 32 µgBase Period: MK-5475 100 µgBase Period: MK-5475 380 µg
Phase 2 Cohort: Mean Change From Baseline in Mean Right Atrial Pressure (mRAP) at 12 Weeks0.3 (-8.0 to 9.0)0.3 (-17.0 to 7.0)-0.5 (-8.0 to 14.0)-0.1 (-14.0 to 12.0)
SecondaryPhase 2 Cohort: Mean Change From Baseline in Cardiac Index (CI) at 12 Weeks

The cardiac index (CI) is a hemodynamic measure that represents the cardiac output (CO) of an individual divided by their body surface area (BSA). Cardiac index is assessed by right heart catheterization (RHC). An increase in CI is indicates better right ventricular function and is associated with a reduction of PAH related morbidity and mortality.

Time frame:
At baseline and 12 weeks
Reported as:
Mean · Liter/minutes/meter square (L/min/m^2)
Phase 2 Cohort: Mean Change From Baseline in Cardiac Index (CI) at 12 Weeks
Liter/minutes/meter square (L/min/m^2)Base Period: PlaceboBase Period: MK-5475 32 µgBase Period: MK-5475 100 µgBase Period: MK-5475 380 µg
Phase 2 Cohort: Mean Change From Baseline in Cardiac Index (CI) at 12 Weeks0.1 (-0.9 to 3.1)0.0 (-1.7 to 1.4)0.2 (-1.4 to 1.5)0.1 (-1.6 to 1.8)
SecondaryPhase 2 Cohort: Mean Change From Baseline in Stroke Volume Index (SVI) at 12 Weeks

The stroke volume index represents the amount of blood in mL, per square meter of body surface area, that is mobilized with each heart beat. SVI is assessed by RHC. An increase in SVI indicates better right ventricular function and is associated with a reduction of PAH related morbidity and mortality.

Time frame:
At baseline and 12 weeks
Reported as:
Mean · mL/beat/m^2
Phase 2 Cohort: Mean Change From Baseline in Stroke Volume Index (SVI) at 12 Weeks
mL/beat/m^2Base Period: PlaceboBase Period: MK-5475 32 µgBase Period: MK-5475 100 µgBase Period: MK-5475 380 µg
Phase 2 Cohort: Mean Change From Baseline in Stroke Volume Index (SVI) at 12 Weeks2.9 (-9.3 to 44.4)0.2 (-37.2 to 20.7)3.2 (-21.8 to 35.2)1.2 (-29.1 to 25.1)
SecondaryPhase 3 Cohort: Mean Change From Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks

6MWD is measured by an exercise test known as 6-Minute Walk Test (6MWT) that assesses functional capacity. It measures the distance covered over a time of 6 minutes and is intended to be used as an outcome measure by which to compare changes in exercise capacity. Each participant's 6MWD is to be measured at baseline and at 24 weeks. An increase in the distance walked during the 6MWT indicates improvement in functional exercise capacity.

Time frame:
At baseline and 24 weeks

No measurements were reported for this outcome.

SecondaryPhase 3 Cohort: Proportion of Participants Whose World Health Organization Functional Class (WHO-FC) is Not Worse at 12 Week Relative to Baseline

The World Health Organization (WHO) classification of functional status is a measure of disease severity, based on a patient's description of their level of functioning and symptoms of disease in relation to their everyday activity. Patients were to be assigned 1 of 4 WHO-FC, dependent on limits of physical activity. As WHO-FC increases from I to IV, limits of physical activity were to increase.

Time frame:
At baseline and 12 weeks

No measurements were reported for this outcome.

SecondaryPhase 2 Cohort: Number of Participants Who Experienced an Adverse Event

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Time frame:
Up to approximately 2.25 years
Reported as:
Count of participants · Participants
Phase 2 Cohort: Number of Participants Who Experienced an Adverse Event
ParticipantsBase Period: PlaceboBase Period: MK-5475 32 µgBase Period: MK-5475 100 µgBase Period: MK-5475 380 µgExtension Period: MK-5475 32 µgExtension Period: MK-5475 100 µgExtension Period: MK-5475 380 μg
Phase 2 Cohort: Number of Participants Who Experienced an Adverse Event27282827333839
SecondaryPhase 2 Cohort: Number of Participants Who Discontinued Study Drug Due to an Adverse Event

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed.

Time frame:
Up to approximately 2.25 years
Reported as:
Count of participants · Participants
Phase 2 Cohort: Number of Participants Who Discontinued Study Drug Due to an Adverse Event
ParticipantsBase Period: PlaceboBase Period: MK-5475 32 µgBase Period: MK-5475 100 µgBase Period: MK-5475 380 µgExtension Period: MK-5475 32 µgExtension Period: MK-5475 100 µgExtension Period: MK-5475 380 μg
Phase 2 Cohort: Number of Participants Who Discontinued Study Drug Due to an Adverse Event0100010
SecondaryPhase 3 Cohort: Number of Participants Who Experienced an Adverse Event

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Time frame:
Up to approximately 2.25 years

No measurements were reported for this outcome.

SecondaryPhase 3 Cohort: Number of Participants Who Discontinued Study Drug Due to an AE

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed.

Time frame:
Up to approximately 2.25 years

No measurements were reported for this outcome.

Adverse events

Collected over Up to approximately 37 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Base Period: Placebo2/41 (4.9%)5/41 (12.2%)18/41 (43.9%)
Base Period: MK-5475 32 µg0/42 (0%)4/42 (9.5%)22/42 (52.4%)
Base Period: MK-5475 100 µg1/44 (2.3%)3/44 (6.8%)23/44 (52.3%)
Base Period: MK-5475 380 µg0/41 (0%)4/41 (9.8%)21/41 (51.2%)
Extension Period: Placebo to MK-5475 32 µg1/11 (9.1%)3/11 (27.3%)7/11 (63.6%)
Extension Period: Placebo to MK-5475 100 µg0/9 (0%)2/9 (22.2%)7/9 (77.8%)
Extension Period: Placebo to MK-5475 380 µg0/10 (0%)4/10 (40%)8/10 (80%)
Extension Period: MK-5475 32 µg0/34 (0%)5/34 (14.7%)24/34 (70.6%)
Extension Period: MK-5475 100 µg0/37 (0%)4/37 (10.8%)28/37 (75.7%)
Extension Period: MK-5475 380 μg2/34 (5.9%)11/34 (32.4%)28/34 (82.4%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventBase Period: PlaceboBase Period: MK-5475 32 µgBase Period: MK-5475 100 µgBase Period: MK-5475 380 µgExtension Period: Placebo to MK-5475 32 µgExtension Period: Placebo to MK-5475 100 µgExtension Period: Placebo to MK-5475 380 µgExtension Period: MK-5475 32 µgExtension Period: MK-5475 100 µgExtension Period: MK-5475 380 μg
Device leakageProduct Issues0/410/420/440/412/110/90/100/340/370/34
Cardiac failureCardiac disorders0/410/420/440/410/111/90/100/340/370/34
PancreatitisGastrointestinal disorders0/410/420/440/410/111/90/100/340/370/34
Multiple organ dysfunction syndromeGeneral disorders0/410/420/440/410/111/90/100/340/370/34
Vulvovaginal wartsNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/410/420/440/410/111/90/100/340/370/34
Atrial flutterCardiac disorders1/410/420/440/410/110/91/100/340/371/34
Complication associated with deviceGeneral disorders0/411/420/440/410/110/91/100/340/370/34
COVID-19Infections and infestations0/410/420/440/410/110/91/100/340/370/34
COVID-19 pneumoniaInfections and infestations0/410/420/440/410/110/91/100/341/370/34
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/410/420/440/410/110/91/100/340/370/34
Most frequent other events
Showing 10 of 108
Most frequent other events
EventBase Period: PlaceboBase Period: MK-5475 32 µgBase Period: MK-5475 100 µgBase Period: MK-5475 380 µgExtension Period: Placebo to MK-5475 32 µgExtension Period: Placebo to MK-5475 100 µgExtension Period: Placebo to MK-5475 380 µgExtension Period: MK-5475 32 µgExtension Period: MK-5475 100 µgExtension Period: MK-5475 380 μg
COVID-19Infections and infestations0/411/423/443/411/111/93/105/346/376/34
Accidental overdoseInjury, poisoning and procedural complications1/413/422/441/410/110/90/108/342/373/34
DiarrhoeaGastrointestinal disorders3/412/422/443/410/112/92/101/341/372/34
Oral candidiasisInfections and infestations0/410/420/440/411/112/90/100/340/370/34
Upper respiratory tract infectionInfections and infestations1/411/422/440/412/112/90/104/344/374/34
HeadacheNervous system disorders4/413/428/446/411/111/91/102/348/374/34
NauseaGastrointestinal disorders0/411/423/443/412/110/92/102/343/371/34
Oedema peripheralGeneral disorders0/410/420/440/411/111/92/101/340/370/34
NasopharyngitisInfections and infestations1/411/421/441/412/111/92/100/345/372/34
Neck painMusculoskeletal and connective tissue disorders1/410/420/440/410/110/92/100/340/370/34

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Base Period: PlaceboBase Period: MK-5475 32 µgBase Period: MK-5475 100 µgBase Period: MK-5475 380 µgTotal
Mean52.1 ± 12.748.1 ± 16.951.7 ± 14.247.6 ± 15.949.9 ± 15.0
Sex: Female, Male
Sex: Female, Male(Participants)Base Period: PlaceboBase Period: MK-5475 32 µgBase Period: MK-5475 100 µgBase Period: MK-5475 380 µgTotal
Female28343230124
Male138121144
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Base Period: PlaceboBase Period: MK-5475 32 µgBase Period: MK-5475 100 µgBase Period: MK-5475 380 µgTotal
Hispanic or Latino1114101247
Not Hispanic or Latino30273329119
Unknown or Not Reported01102
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Base Period: PlaceboBase Period: MK-5475 32 µgBase Period: MK-5475 100 µgBase Period: MK-5475 380 µgTotal
American Indian or Alaska Native30003
Asian31004
Native Hawaiian or Other Pacific Islander00000
Black or African American23117
White32344136143
More than one race142411
Unknown or Not Reported00000
08

Study locations

91 sites
  • University of California San Diego Health-Pulmonary Critical Care ( Site 0061)
    La Jolla, California 92037-7381, United States
  • University of California Davis Health-Internal Medicine: Pulmonary, Critical Care and Sleep Medicine
    Sacramento, California 95817, United States
  • UCSF Helen Diller Medical Center at Parnassus Heights ( Site 0063)
    San Francisco, California 94143, United States
  • University of Colorado - Denver ( Site 0003)
    Aurora, Colorado 80045, United States
  • Cardiovascular Institute of North Colorado - Banner Health ( Site 0013)
    Greeley, Colorado 80631, United States
  • Georgetown University Hospital ( Site 0025)
    Washington, District of Columbia 20007, United States
  • University of Miami Hospital-Division of Pulmonary & Critical Care ( Site 0053)
    Miami, Florida 33136, United States
  • AdventHealth Orlando ( Site 0040)
    Orlando, Florida 32803, United States
  • Tampa General Hospital ( Site 0058)
    Tampa, Florida 33606, United States
  • Indiana University Health Methodist Hospital ( Site 0045)
    Indianapolis, Indiana 46202-1239, United States
  • University of Iowa Hospital and Clinics ( Site 0009)
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center ( Site 0038)
    Kansas City, Kansas 66160, United States
  • University of Kentucky ( Site 0006)
    Lexington, Kentucky 40536, United States
  • Norton Pulmonary Specialists ( Site 0048)
    Louisville, Kentucky 40202, United States
  • University of Maryland ( Site 0032)
    Baltimore, Maryland 21201, United States
  • Washington University School of Medicine ( Site 0066)
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center ( Site 0041)
    Omaha, Nebraska 68198, United States
  • University of New Mexico, Health Sciences Center ( Site 0028)
    Albuquerque, New Mexico 87131, United States
  • Clinical Trials Unit at Eastowne Medical Office Building ( Site 0019)
    Chapel Hill, North Carolina 27514, United States
  • AnMed Health ( Site 0033)
    Anderson, South Carolina 29621, United States
  • Statcare Pulmonary Consultants ( Site 0067)
    Knoxville, Tennessee 37934, United States
  • University of Texas Southwestern Medical Center at Dallas ( Site 0012)
    Dallas, Texas 75390, United States
  • Houston Methodist Research Institute ( Site 0036)
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at Houston ( Site 0054)
    Houston, Texas 77030, United States
  • Sentara Norfolk General Hospital ( Site 0014)
    Norfolk, Virginia 23507, United States
  • West Virginia University-WVU Heart and Vascular Institute ( Site 0051)
    Morgantown, West Virginia 26506, United States
  • Cardiologia Palermo ( Site 0140)
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1425BNG, Argentina
  • Hospital El Cruce Nestor Carlos Kirchner ( Site 0132)
    Florencio Varela, Buenos Aires 1888, Argentina
  • Centro Medico Capital ( Site 0131)
    La Plata, Buenos Aires B1904AAW, Argentina
  • Hospital Universitario Austral ( Site 0138)
    Pilar, Buenos Aires B1629ODT, Argentina
  • Instituto de Investigaciones Clinicas Quilmes ( Site 0141)
    Quilmes, Buenos Aires B1878GEG, Argentina
  • Sanatorio de la Trinidad Mitre ( Site 0130)
    Buenos Aires, Caba 1039, Argentina
  • Instituto Cardiovascular de Rosario ( Site 0128)
    Rosario, Santa Fe S2000DSR, Argentina
  • Hospital Privado Universitario de Córdoba ( Site 0137)
    Cordoba, X5016KEH, Argentina
  • Nepean Hospital ( Site 0184)
    Kingswood, New South Wales 2747, Australia
  • Macquarie University ( Site 0180)
    Macquarie University, New South Wales 2109, Australia
  • John Hunter Hospital ( Site 0185)
    Newcastle, New South Wales 2305, Australia
  • Université Libre de Bruxelles - Hôpital Erasme ( Site 0601)
    Brussels, Bruxelles-Capitale, Region De 1070, Belgium
  • UZ Leuven ( Site 0600)
    Leuven, Vlaams-Brabant 3000, Belgium
  • Peter Lougheed Centre ( Site 0107)
    Calgary, Alberta T1Y 6J4, Canada
  • University Health Network - Toronto General Hospital ( Site 0104)
    Toronto, Ontario M5G 2N2, Canada
  • IUCPQ ( Site 0111)
    Quebec, G1V 4G5, Canada
  • Centro Cardiovascular Colombiano Clínica Santa María ( Site 0154)
    Medellín, Antioquia 050034, Colombia
  • Hospital Universitario San Ignacio ( Site 0152)
    Bogota, Distrito Capital De Bogota 110231, Colombia
  • Fundacion Cardiovascular de Colombia ( Site 0155)
    Piedecuesta, Santander 681017, Colombia
  • CHRU Brest - Hopital Cavale Blanche ( Site 0254)
    Brest, Finistere 29609, France
  • CHU de Toulouse - Hopital Larrey ( Site 0258)
    Toulouse, Haute-Garonne 31059, France
  • Institut Coeur Poumon - CHRU de Lille ( Site 0252)
    Lille Cedex, Nord-Pas-de-Calais 59037, France
  • Centre Hospitalier Universitaire de Rouen ( Site 0253)
    Rouen, Seine-Maritime 76031, France
  • CHU - Hopital de Bicetre ( Site 0251)
    Le Kremlin-Bicetre, Val-de-Marne 94275, France
  • Thoraxklinik Heidelberg gGmbH am Universitaetsklinikum Heidelberg ( Site 0276)
    Heidelberg, Baden-Wurttemberg 69126, Germany
  • Klinikum Würzburg Mitte-Medizinische Klinik - Schwerpunkt Pneumologie & Beatmungsmedizin ( Site 0280
    Wuerzburg, Bayern 97074, Germany
  • UKGM Gießen/Marburg ( Site 0279)
    Gießen, Hessen 35392, Germany
  • Medizinische Hochschule Hannover ( Site 0284)
    Hannover, Niedersachsen 30625, Germany
  • Uniklinikum Dresden ( Site 0283)
    Dresden, Sachsen 01307, Germany
  • Universitaetsklinikum Leipzig ( Site 0285)
    Leipzig, Sachsen 04103, Germany
  • AHEPA University General Hospital of Thessaloniki ( Site 0577)
    Thessaloniki, 54636, Greece
  • Soroka Medical Center ( Site 0330)
    Beer Sheva, 8410101, Israel
  • Rambam Medical Center ( Site 0335)
    Haifa, 3109601, Israel
  • Wolfson Medical Center [Holon, Israel] ( Site 0333)
    Holon, 5810000, Israel
  • Shaare Zedek Medical Center ( Site 0331)
    Jerusalem, 9103102, Israel
  • Rabin Medical Center ( Site 0327)
    Petah Tikva, 4941492, Israel
  • University of Naples Federico II ( Site 0308)
    Naples, Campania 80100, Italy
  • Azienda Ospedaliera Policlinico Umberto I ( Site 0301)
    Roma, Lazio 00161, Italy
  • Ospedale San Gerardo - ASST Monza ( Site 0304)
    Monza, Monza E Brianza 20900, Italy
  • Centro Cardiologico Monzino IRCCS ( Site 0306)
    Milano, 20138, Italy
  • Fondazione IRCCS Policlinico San Matteo ( Site 0302)
    Pavia, 27100, Italy
  • Consultorio 1020 Hospital Angeles Xalapa ( Site 0654)
    Xalapa, Veracruz 91193, Mexico
  • Operadora de Hospitales Angeles. S.A. de C.V. -Sucursal Lomas ( Site 0653)
    Huixquilucan, 52763, Mexico
  • Instituto Nacional de Cardiología -Ignacio Chavez ( Site 0651)
    Mexico D.F, 14080, Mexico
  • Christchurch Hospital ( Site 0201)
    Christchurch, Canterbury 8011, New Zealand
  • Greenlane Clinical Centre ( Site 0203)
    Auckland, 1051, New Zealand
  • Specjalistyczny Szpital im. Dr Alfreda Sokolowskiego w Walbrzychu ( Site 0351)
    Walbrzych, Dolnoslaskie 58-309, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie ( Site 0352)
    Lublin, Lubelskie 20-954, Poland
  • Krakowski Szpital Specjalistyczny im. Jana Pawa II-Oddzial Kliniczny Chorob Serca i Naczyn z Pododd
    Krakow, Malopolskie 31-202, Poland
  • Scientific Research Institute Complex Problems Cardiovascular Disease ( Site 0403)
    Kemerovo, Kemerovskaya Oblast 650002, Russian Federation
  • Almazov National Medical Research Centre of the Ministry of Health ( Site 0402)
    Saint Petersburg, Sankt-Peterburg 197341, Russian Federation
  • Akademiska sjukhuset ( Site 0453)
    Uppsala, Uppsala Lan 751 85, Sweden
  • Sahlgrenska Universitetssjukhuset-Cardiology Research Unit ( Site 0452)
    Gothenburg, Vastra Gotalands Lan 413 45, Sweden
  • Ege Universitesi Hastanesi-Cardilogy Department ( Site 0504)
    Bornova, Izmir 35100, Turkey
  • Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 0510)
    Ankara, 06100, Turkey
  • Akdeniz Uni.Tip Fakultesi Saglik Uygulama ve Arastirma Merkezi ( Site 0508)
    Antalya, 07059, Turkey
  • Eskisehir Osmangazi Uni. Tip Fakultesi Hastanesi ( Site 0506)
    Eskisehir, 26040, Turkey
  • Istanbul Uni. Kardiyoloji Enstitusu ( Site 0502)
    Istanbul, 34096, Turkey
  • Istanbul Universitesi Istanbul Tip Fakultesi ( Site 0509)
    Istanbul, 34390, Turkey
  • Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 0501)
    Istanbul, 34899, Turkey
  • Dokuz Eylul University Faculty of Medicine ( Site 0505)
    Izmir, 35330, Turkey
  • Golden Jubilee National Hospital ( Site 0556)
    Glasgow, Glasgow City G81 4DY, United Kingdom
  • Royal Brompton and Harefield NHS Trust ( Site 0553)
    London, London, City Of SW3 6NP, United Kingdom
  • Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 0554)
    London, London, City Of W12 0HS, United Kingdom
  • The Freeman Hosp.Newcastle upon Tyne Hosp NHS Trust ( Site 0552)
    Newcastle-upon-Tyne, Newcastle Upon Tyne NE7 7DN, United Kingdom
09

References and documents

Publications

  • Humbert M, Hassoun PM, Chin KM, Bortman G, Patel MJ, La Rosa C, Fu W, Loureiro MJ, Hoeper MM. MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study. Eur Respir J. 2024 Nov 14;64(5):2401110. doi: 10.1183/13993003.01110-2024. Print 2024 Nov. PubMed 39255991 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Jan 2024, 31 months.

Results were first posted in Feb 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2021
First posted
Feb 1, 2021
StartActual
May 19, 2021
Primary completionActual
Jan 4, 2024
CompletionActual
Jul 2, 2024
Results first posted
Feb 21, 2025
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04732221
Responsible party
Sponsor
First posted
Feb 1, 2021
Start date
May 19, 2021
Primary completion
Jan 4, 2024
Completion
Jul 2, 2024
Results posted
Feb 21, 2025
Last update
May 25, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Frespaciguat

Start the discussion